All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @cate.elam on TikTok · 461s|Watch on TikTok

@cate.elam's semaglutide discontinuation claims, fact-checked

Cate Elam

TikTok creator

721.7K viewsWatch on TikTok

Quick answer

Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying. The STEP 1 trial showed 14.9% body weight loss at 68 weeks with 2.4mg weekly dosing, but most participants regain weight when discontinuing the medication.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @cate.elam's semaglutide discontinuation claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@cate.elam's semaglutide discontinuation claims, fact-checked" from Cate Elam. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying.

The reason this review is not generic is the source wording and the canonical claim label "glp1 getting off semaglutide after 15 months hold me accountable." In this clip, the useful excerpt is: "getting off semaglutide after 15 months, hold me accountable" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Clinical guidelines recommend indefinite semaglutide use for sustained weight management, not 15-month courses
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying. The STEP 1 trial showed 14.9% body weight loss at 68 weeks with 2.4mg weekly dosing, but most participants regain weight when discontinuing the medication.
  • STEP 1 trial extension found participants regained 11.6% of body weight within a year of stopping semaglutide
  • Clinical guidelines recommend indefinite semaglutide use for sustained weight management, not 15-month courses

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial extension found participants regained 11.6% of body weight within a year of stopping semaglutide
  • Clinical guidelines recommend indefinite semaglutide use for sustained weight management, not 15-month courses
  • STEP 4 trial showed participants regained two-thirds of lost weight over 52 weeks after discontinuation
  • Semaglutide works by mimicking GLP-1 hormone; stopping eliminates these appetite-regulating effects
  • Weight regain after stopping isn't due to lack of willpower but predictable hormonal changes
  • Monthly semaglutide costs range from $1,000-1,500 without insurance coverage
  • Discontinuation decisions should involve healthcare providers, not social media accountability

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

TikTok creator Cate Elam posted about stopping semaglutide after 15 months, asking her 721.7K viewers to hold her accountable. While the video doesn't make specific medical claims, the decision to discontinue raises important questions about what happens when people stop GLP-1 medications.

What does this video actually claim?

The video shows Elam announcing her decision to stop semaglutide after 15 months of use. She doesn't make explicit claims about side effects or reasons for stopping, but asks for accountability from her audience regarding life after the medication.

The hashtags (#semaglutideweightloss, #lifeaftersemaglutide) suggest she's positioning this as educational content about the post-medication experience. This type of content has become increasingly common as more people share their GLP-1 journeys on social media.

What's missing is context about why she's stopping or what her healthcare provider recommended. The accountability request implies she expects challenges ahead.

What happens when people stop semaglutide?

The research is clear: most people regain weight when they stop semaglutide. The STEP 1 trial extension (Wilding et al., NEJM, 2022) found participants regained 11.6% of their body weight within a year of stopping the medication.

This isn't a failure of willpower. Semaglutide works by mimicking GLP-1, a hormone that regulates appetite and blood sugar. When you stop taking it, those hormonal effects disappear.

The STEP 4 trial specifically studied this discontinuation effect. Participants who switched from semaglutide to placebo regained two-thirds of their lost weight over 52 weeks, while those who continued the medication maintained their weight loss.

Is 15 months a typical treatment duration?

Fifteen months isn't unusually short for semaglutide use, but it's not the intended duration either. Clinical trials like STEP 1 ran for 68 weeks (about 16 months), but the medication is designed for long-term use.

Most clinical guidelines suggest semaglutide should be continued indefinitely for weight management, similar to medications for diabetes or high blood pressure. The FDA approval for Wegovy (the weight management formulation) doesn't specify a stopping point.

People stop for various reasons: cost (around $1,000-1,500 monthly without insurance), side effects, or personal preference. However, stopping typically means losing the metabolic benefits the medication provided.

What should viewers actually know?

Elam's experience will likely mirror what clinical trials show: gradual weight regain over 6-12 months. This isn't a personal failing but a predictable biological response to stopping a medication that affects hunger hormones.

The "accountability" framing, while well-intentioned, might inadvertently promote the idea that willpower alone can maintain semaglutide's effects. The evidence suggests otherwise.

If someone is considering stopping semaglutide, they should discuss strategies with their healthcare provider. Some doctors recommend lifestyle interventions, other medications, or planned breaks rather than abrupt discontinuation. The decision should be medical, not social media-driven.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Cate Elam · TikTok creator

721.7K views on this video

getting off semaglutide after 15 months, hold me accountable #semaglutide #semaglutideweightloss #lifeaftersemaglutide #weightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial extension found participants regained 11.6% of body?

STEP 1 trial extension found participants regained 11.6% of body weight within a year of stopping semaglutide

What does the video say about clinical guidelines recommend indefinite semaglutide use for sustained weight management,?

Clinical guidelines recommend indefinite semaglutide use for sustained weight management, not 15-month courses

What does the video say about step 4 trial showed participants regained two-thirds of lost weight?

STEP 4 trial showed participants regained two-thirds of lost weight over 52 weeks after discontinuation

What does the video say about semaglutide works by mimicking glp-1 hormone; stopping eliminates these appetite-regulating?

Semaglutide works by mimicking GLP-1 hormone; stopping eliminates these appetite-regulating effects

What does the video say about weight regain after stopping?

Weight regain after stopping isn't due to lack of willpower but predictable hormonal changes

What does the video say about monthly semaglutide costs range from $1,000-1,500 without insurance coverage?

Monthly semaglutide costs range from $1,000-1,500 without insurance coverage

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Cate Elam, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.